Veradermics, Incorporated (MANE) Financials
MANE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 825.7 million | 12.1 million |
| March 31, 2026 | 398.6 million | 6.7 million |
| Dec. 31, 2025 | 152.6 million | 273.6 million |
| Sept. 30, 2025 | 18.8 million | 114.8 million |
MANE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -14.5 million | 3.5 million |
| March 31, 2026 | -21.2 million | 5.3 million |
| Dec. 31, 2025 | -23.6 million | 974000 |
| Sept. 30, 2025 | ? | ? |
MANE Net Income
No data available :(
MANE Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 819.9 million | - | 428000 |
| March 31, 2026 | 390.8 million | - | - |
| Dec. 31, 2025 | 141.9 million | - | 4000 |
| Sept. 30, 2025 | 15.1 million | - | 16000 |
MANE Shares Outstanding
MANE Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 21000 | 18.6 million | 10.9 million | - |
| March 31, 2026 | - | 20.9 million | 8.9 million | - |
| Dec. 31, 2025 | 5000 | 18.2 million | 4.8 million | - |
| Sept. 30, 2025 | - | - | - | - |
MANE Cost of Revenue
No data available :(
MANE
Price: $112.71
52 week price:
Earnings Per Share: -2.65 USD
Exchange: NYQ
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 4.6 billion